5-alpha reductase inhibitors use in prostatic disease and beyond. [PDF]
Transl Androl Urol, 2023 Chislett B +5 more
europepmc +1 more source
Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer. [PDF]
J Transl Med, 2023 Seok J +6 more
europepmc +1 more source
Design, Synthesis, and Evaluation of a Luminescent Cholesterol Mimic. [PDF]
J Org Chem, 2021 Work EM +10 more
europepmc +1 more source
Mce3R Stress-Resistance Pathway Is Vulnerable to Small-Molecule Targeting That Improves Tuberculosis Drug Activities. [PDF]
ACS Infect Dis, 2019 Yang X +10 more
europepmc +1 more source
Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives. [PDF]
Oxid Med Cell Longev, 2022 Semwal P +14 more
europepmc +1 more source
Discovery and development of steroidal enzyme inhibitors as anti-cancer drugs: state-of-the-art and future perspectives. [PDF]
J Enzyme Inhib Med ChemCerra B, Gioiello A.
europepmc +1 more source
Recurrent Anti-AMPA Receptor Limbic Encephalitis: A Case Report and Literature Review. [PDF]
Front Neurol, 2021 Fang Y, Pan D, Huang H.
europepmc +1 more source
Synthesis of benzo[c]quinolizin-3-ones: selective non steroidal inhibitors of steroid 5a-Reductase 1 [PDF]
, 1998 Comerci, A. +7 more
core
Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia. [PDF]
Int J UrolInamura S +9 more
europepmc +1 more source